Healthcare
Medtronic plc(MDT)
Live Price
Offline$80.20
-0.16% today
1Y Change
-5.41%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $102.71B
- Revenue Growth
- +3.6%
- EPS Growth
- +31.0%
- Dividend Yield
- 3.5%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Medtronic plc (MDT) is a Healthcare stock with a market cap of $102.71B and listed on NYSE. The stock last traded around $80.20 and down 5.4% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of +3.6%, EPS growth of +31.0%, a dividend yield of 3.5%. What stands out right now is revenue +3.6%, EPS +31.0%, free cash flow -0.3% with operating margin 17.9% and ROIC 6.4%. The dividend matters to the case here, with a current yield around 3.5%. Valuation is more restrained than many high-expectation growth names at P/E 22.2 and price/sales 2.9. Stock Foundry combines MDT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+3.6% vs +7.6% peer median
Operating Margin
Near sector median
+17.9% vs +19.4% peer median
P/E
Below sector median
22.2 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 20, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +3.6% and EPS at +31.0%, with operating margin around 17.9%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 3.5%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.5% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 20, 2026 | โ | +0.0% | -3.3% | โ |
2026 Feb 17, 2026 | +1.5% | +2.2% | +0.4% | -8.3% |
2025 Nov 18, 2025 | +3.8% | -0.5% | +4.5% | -2.5% |
Benchmark Edge
MDT vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MDT
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MDT Max Drawdown
-30.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MDT and SPY.
Company Overview
Medtronic plc
New York Stock Exchange
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
- Leadership
- Geoffrey Straub Martha
- IPO Date
- May 2, 1973
- Employees
- 95.0k
- Street Address
- Building Two, Parkmore Business Park West
- Mailing
- Galway, 2
- Region
- Galway, IE
- Reporting Currency
- USD
- Investor Line
- 353 1 438 1700
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 22.2
- EV/EBITDA
- 13.9
- Price/Sales
- 2.9
- Price/Book
- 2.1
Growth
- Revenue
- +3.6%
- EPS
- +31.0%
- Free Cash Flow
- -0.3%
Profitability
- Gross Margin
- 61.9%
- Operating Margin
- 17.9%
- Net Margin
- 13.0%
- ROE
- 9.5%
- ROIC
- 6.4%
Balance Sheet
- Debt/Equity
- 0.57
- Current Ratio
- 2.54
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.